Investigation info Side Effects of Risperdal
Stueve Siegel Hanson is investigating claims concerning Gynecomastia, a side effect of the drug Risperdal. Gynecomastia is the development of abnormal breast tissue in males treated with the prescription medication.
Risperdal is an antipsychotic drug that is used to treat an array of conditions including schizophrenia, bipolar disorder, and other behavioral and psychological conditions. Risperdal is made by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson and was first approved by the FDA (Food and Drug Administration) in 1993. The drug was not approved for treatment in children until 2006.
Risperdal manufacturer, Janssen Pharmaceuticals, Inc., does not dispute that the drug may be associated with Gynecomastia, in which young males develop breast tissue as a result of the production of the hormone prolactin, the same hormone that stimulates breast development and milk production in women. In fact, the manufacturer’s own studies have confirmed that more than 80 % of young Risperdal patients being treated for schizophrenia or bipolar disorder experienced increased prolactin levels. Similarly, nearly half of all young Risperdal patients suffering from disorders besides schizophrenia or bipolar disorder experienced increased prolactin levels.
Abnormal growth of breast tissue in boys can be damaging and devastating, both socially and emotionally, and physical problems may include:
- Abnormal Breast Growth
- Nipple Discharge
In many instances, surgery may be necessary to remove the unwanted breast tissue.
It has been alleged that Johnson & Johnson failed to provide adequate warnings about this devastating side effect and to properly research the drug.
If you or someone you know has experienced Gynecomastia, the development of abnormal breast tissue in males treated with Risperdal, and wish to receive additional information about your legal options, please call 1.888.756.6494.